Dan Lemaitre joined BlueWind Medical, an Israel neuromodulation development company as Executive Chairman in September 2018. He also serves as Chairman of Endologix (NYSE: ELGX) a Irvine California company that is focused on aortic disorders with ~$150 million in annual sales and 650 employees. He is also on the board of Globus Medical (NYSE: GMED) one of the fastest growing spinal companies with revenue of ~$700 million per annum. Previously, Mr. Lemaitre was the CEO of CoreValve that launched the first commercial transcatheter aortic valve in Europe in 2007. By 2009 revenue were at a $100 million annualized run rate. Dan led negotiations that resulted in the sale of CoreValve to Medtronic in a transaction valued at $800 million. Prior to joining CoreValve, Mr. Lemaitre was a Senior Vice President at Medtronic where he headed-up strategic planning and corporate development. Earlier in his career Dan spent 28 years in the medical device field as an investment analyst.
19 consecutive years, capturing first place honors 8 times as the top-ranked medical device analyst in the country.